Novartis (NVS) to Announce Earnings on Tuesday

Novartis (NYSE:NVS) is projected to post its Q2 2026 results before the market opens on Tuesday, July 21st. Analysts expect Novartis to announce earnings of $2.17 per share and revenue of $14.0665 billion for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 21, 2026 at 11:40 AM ET.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing the consensus estimate of $2.11 by ($0.12). Novartis had a return on equity of 38.82% and a net margin of 24.87%.The firm had revenue of $13.52 billion for the quarter, compared to analysts’ expectations of $13.44 billion. During the same quarter last year, the firm posted $2.28 earnings per share. Novartis’s quarterly revenue was down .9% on a year-over-year basis. On average, analysts expect Novartis to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Novartis Price Performance

Shares of Novartis stock opened at $153.78 on Monday. The stock has a market capitalization of $293.44 billion, a P/E ratio of 22.03, a PEG ratio of 2.65 and a beta of 0.45. The business has a 50 day simple moving average of $151.41 and a two-hundred day simple moving average of $151.69. Novartis has a 12 month low of $112.34 and a 12 month high of $170.46. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NVS. Glenview Trust co raised its holdings in Novartis by 2.3% in the 2nd quarter. Glenview Trust co now owns 3,800 shares of the company’s stock valued at $460,000 after acquiring an additional 84 shares during the last quarter. CreativeOne Wealth LLC boosted its holdings in shares of Novartis by 3.6% during the third quarter. CreativeOne Wealth LLC now owns 2,545 shares of the company’s stock worth $326,000 after purchasing an additional 88 shares during the last quarter. Pin Oak Investment Advisors Inc. boosted its holdings in shares of Novartis by 25.2% during the third quarter. Pin Oak Investment Advisors Inc. now owns 462 shares of the company’s stock worth $59,000 after purchasing an additional 93 shares during the last quarter. Rehmann Capital Advisory Group grew its position in shares of Novartis by 1.7% in the third quarter. Rehmann Capital Advisory Group now owns 5,617 shares of the company’s stock valued at $720,000 after purchasing an additional 96 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in shares of Novartis by 0.9% in the second quarter. Smartleaf Asset Management LLC now owns 11,637 shares of the company’s stock valued at $1,397,000 after purchasing an additional 99 shares during the period. 13.12% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on NVS shares. Morgan Stanley boosted their price target on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research report on Thursday, March 26th. Weiss Ratings lowered Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $141.20.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.